Abbrea Capital’s DexCom DXCM Stock Holding History

Abbrea Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,836	Closed	-$246K	–	242
2021 Q4	$246K	Hold	1,836	–	–	0.03%	230
2021 Q3	$251K	Buy	+1,836	New	+$232K	0.04%	219

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Abbrea Capital's DXCM Position: Q1 2022 in Review

Abbrea Capital sold out of DexCom (DXCM) in Q1 2022, closing a stake of 1,836 shares — an estimated $246K sold.

Abbrea Capital first reported a position in DXCM in Q3 2021 and held it in 2 quarters. The position peaked at $251K in Q3 2021. 861 funds tracked by Wall St. Rank hold DXCM as of Q1 2022.

Abbrea Capital reported no remaining DexCom position as of Q1 2022 after selling out during the quarter.
Abbrea Capital sold 1,836 DexCom shares in Q1 2022, an estimated $246K.
Abbrea Capital first reported a position in DexCom in Q3 2021 and held it in 2 quarters.
Abbrea Capital's DexCom position peaked at $251K in Q3 2021.
861 funds tracked by Wall St. Rank held DexCom as of Q1 2022.

Based on Abbrea Capital's 13F filing for Q1 2022, filed 11 May 2022.